Chondrocyte-Alginate Gel Suspension
Vesicoureteral Reflux
FDA Office of Orphan Products DevelopmentCell therapyPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Vesicoureteral Reflux cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Hans Bahlmann | Phase 3 | B |
NEPENTHE Hans Bahlmann | Phase 3 | B |
LIDOCAINE Hans Bahlmann | Phase 3 | B |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →